BlueWind Medical’s Revi™ System Secures U.S. FDA De Novo Classification Grant for the Treatment of Urgency Incontinence

Revi redefines the treatment of Urgency Incontinence with a patient-centric implantable tibial neuromodulation solution that empowers patients PARK CITY, Utah, Aug. 17, 2023 /PRNewswire/ — BlueWind Medical, Ltd. today announced that the US Food and Drug Administration (FDA) granted a De…

Click here to view original post